ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/pan-RAS-inhibitor-tricomplex-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/pan-RAS-inhibitor-tricomplex-inhibitor
4
trial(s) found.
NCT07678593
Advanced
Phase 1 / Phase 2
Not yet recruiting
A Multi-center, Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH276 in Combination With Cetuximab or Chemotherapy in the Treatment of Patients With Advanced Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation (
GFH276X0201
)
anti-EGFR monoclonal antibody
pan-RAS inhibitor,tricomplex inhibitor
Cancer
Pancreatic adenocarcinoma
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
VIC
3066 - Epping - Northern Hospital
3168 - Clayton - Monash Medical Centre
3199 - Frankston - PASO Medical
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT07491445
Advanced
Phase 3
Recruiting
RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma (
RASolute-303
)
antimetabolite
pan-RAS inhibitor,tricomplex inhibitor
taxane
Pancreatic adenocarcinoma
Pancreatic adenosquamous carcinoma
Pancreatic cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
NCT06881784
Advanced
Phase 3
Recruiting
RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC (
RASolve-301
)
pan-RAS inhibitor,tricomplex inhibitor
taxane
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2217 - Kogarah - St George Private Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06162221
Advanced
Phase 1 / Phase 2
Recruiting
A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC) (
RMC-LUNG-101
)
Carboplatin
Cisplatin
Daraxonrasib
Elironrasib
HRAS inhibitor
KRAS G12C inhibitor
KRAS G12C inhibitor,tricomplex inhibitor
KRAS G12D inhibitor
KRAS G12D inhibitor,tricomplex inhibitor
KRAS inhibitor
KRAS inhibitor,ON-state
KRAS inhibitor,mutant selective
KRAS inhibitor,tricomplex inhibitor
NRAS inhibitor
Pembrolizumab
Pemetrexed
Zoldonrasib
anti-PD-1 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,KRAS-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cytotoxic chemotherapy
immune checkpoint blockade
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,PD-1-targeting
pan-KRAS inhibitor
pan-RAS inhibitor
pan-RAS inhibitor,tricomplex inhibitor
platinum-based antineoplastic agent
+ pan-RAS inhibitor,tricomplex inhibitor
Cancer
Lung cancer
Non-small cell lung cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (3)
Not yet recruiting (1)
Recruitment Country and State
NSW (4)
VIC (3)
WA (2)
SA (1)
NZ (1)
QLD (1)
Phase
Phase 1 / Phase 2 (2)
Phase 3 (2)
Trial Type
Advanced (4)
Cancer Therapy Class
KRAS
100%
EGFR
25%
PD-1
25%
PD-1/PD-L1
25%
Facility
3168 - Clayton - Monash Medical Centre (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
2109 - North Ryde - Macquarie University Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
3066 - Epping - Northern Hospital (1)
3199 - Frankston - PASO Medical (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2217 - Kogarah - St George Private Hospital (1)
3004 - Melbourne, Southbank - Alfred Health (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
6009 - Nedlands - Linear Clinical Research (1)
Cancer Type
Cancer
Solid tumour
Exocrine pancreatic cancer
Gastrointestinal cancer
Pancreatic adenocarcinoma
Pancreatic cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Pancreatic adenosquamous carcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy